Healius Ltd (ASX: HLS) Share Price and News

Mr Hall has included roles as Chair, Non-Executive Director and Chief Investment Officer, along with senior executive positions in Australia and Hong Kong. Mr Halls current roles include Chair of BiomeBank, Non-Executive Director, Investment Committee Member and Audit Committee Member of AMP Superannuation, Non-Executive Director and Audit Committee Member of Funds SA, Investment Committee Chair of Perks Private Wealth, and Member of the Advisory Board to the Long-Term Value Fund at Tanarra Capital.

Professor Mattick was Chief Executive of Genomics England, which was established by the United Kingdom government to foster the use of genetic information in healthcare. He was Director of the Garvan Institute of Medical Research in Sydney from 2012 to 2018, where he established high throughput NATA accredited DNA sequencing and genome analysis facilities. He was a member of the Australian Health Ethics Committee (AHEC) of the National Health & Medical Research Council (NHMRC) from 1997 to 2003, an advisor to the Australian Law Reform Commissions Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health, and the AHEC Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology. He was appointed an Officer of the Order of Australia in 2001 for services to scientific research in the fields of molecular biology, genetics and biotechnology. He is a member of the Risk Management Committees.

Mr Anderson was appointed as Chief Executive Officer in March 2024. Prior to this, he held the position of Group Chief Financial Officer of Healius. He is an experienced business leader with a background in industries facing significant disruption. He was previously Chief Executive Officer of Network Ten and more recently, Executive Vice President at Viacom CBS Networks Australia & New Zealand. He also spent more than a decade working abroad at CLS Holdings plc in London and KPMG in New Zealand.

Prof Robinson is a physician, academic, and advisor with over 25 years experience as a leader in healthcare. In addition to being a practising endocrinologist, Professor Robinson currently serves as a Non-Executive Director of listed healthcare entities Cochlear Limited (ASX:COH) (since 13 December 2016) and Mayne Pharma Group Limited (ASX:MYX) (since 26 August 2014). He is also a Non-Executive Director of British speciality pharmaceutical company CS Pharmaceuticals Ltd (since 24 October 2024), a Senior Advisor to McKinsey & Company and an advisor to Minter Ellison. Professor Robinsons former roles include Chair of the Australian Governments taskforce of expert clinicians charged with reviewing the Medicare Benefits Schedule, the Medical Benefits Schedule Review Taskforce, and chair of Australias peak advisory and funding body for medical research, the National Health and Medical Research Council. He is a former Dean of the University of Sydneys Medical School, the former head of the Cancer Genetics Unit at the Kolling Institute, Royal North Shore Hospital, and the former Head, Division of Medicine, Royal North Shore Hospital.

Ms McKenzie is a member of the Boards Risk Management Committee and People, Governance and Remuneration Committee. She is an experienced Chief Executive Officer and Non Executive Director. Her executive career included over 30 years of experience in the telecommunication and government sectors in Australia, New Zealand and Hong Kong. She was most recently the Chief Executive Officer of Chorus. Prior to this, she held several senior roles at Telstra, including Chief Operating Officer, where she oversaw the groups property portfolio, and seven years in senior roles in NSW Government, including the Department of Commerce and Department of Industrial Relations. She is a member of Chief Executive Women, has served on the Telstra Foundation.

Ms Evans was appointed as a Non Executive Director. She is the Chair of the Boards People, Governance and Remuneration Committee and is a member of the Risk Management Committee. She has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region.

Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG and has experience in the aged care and healthcare sectors, having established and led KPMGs Health, Aging and Human Services audit practice. During her 24 years with KPMG, she worked in Australia, the US, Asia and UK. She is a member of the People and Governance Committee.

Mr Taylor has over 30 years of experience in international advisory having recently retired as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australias private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. He initiated multiyear research efforts on healthcare, COVID response, productivity and innovation and has published research articles and reports on healthcare reform lessons from around the globe. He is currently a part time senior board advisor at McKinsey for the Health and Public Sector practice, a member of the strategic advisory committee For Purpose Investment Partners and was recently appointed as Chair of the NSW Innovation and Productivity Commission. He is the Honorary Federal Treasurer for the Liberal Party and a Board member on the Federal Executive. He is a member of both the People and Governance Committees.

Mr Rubic will bring to the Board 25 years of executive leadership in healthcare. He has held CEO positions at St Vincents and Mater Health Sydney, I-MED Radiology Network and Healthscope. He is also a Non-Executive Director. Mr Rubic is currently a Non Executive Director of the Mater Hospitals Group, Pacific Smiles Group Limited (ASX:PSQ) and Catholic Healthcare Limited. He is also Deputy Chair of TPG private equity owned InvoCare.

-

-

-

-

-

-

-

-

-

-

-